Table 1.

Selected published reports of very early nusinersen initiation in SMA.

Study	SMN2 copies	Symptomatic at first dose	Age at first dose	Diagnostic setting/baseline features	Follow-up/reported outcome
Unver et al.	2	No	7 h	Prenatal diagnosis; absent DTRs	Normal development reported at 13 months
Unver et al.	3	No	3 days	Prenatal diagnosis; no overt SMA manifestations	Normal development reported at almost 6 years
Nishino et al.	2	Yes	55 days	Postnatal diagnosis; hypotonia, absent DTRs	Respiratory and feeding deterioration reported at 6 months
Present case	2	Yes	5 days	Postnatal diagnosis; generalized hypotonia, markedly reduced spontaneous movement, weak cry, tongue fasciculations, absent DTRs	Four loading doses completed by day 68; CHOP-INTEND increased from 6 to 30; no procedure-related adverse events

The table includes selected published individual-level neonatal cases of very early nusinersen initiation with sufficient clinical detail for direct comparison. DTRs, deep tendon reflexes; SMA, spinal muscular atrophy.